Who holds the patent for Amlodipine?

Introduction to Amlodipine

Overview of Amlodipine 
Amlodipine is a calcium channel blocker that has become a cornerstone in the treatment of hypertension and certain forms of angina. It is well recognized for its efficacy in lowering blood pressure by relaxing arterial smooth muscle, which leads to improved blood flow and reduced workload on the heart. Over the years, numerous formulations have emerged, ranging from oral tablets to liquid formulations and even fixed-dose combinations. The breadth of these developments reflects the drug’s widespread use and the ongoing efforts within the industry to optimize its delivery, stability, and patient adherence.

Medical Uses and Benefits 
Medically, amlodipine is primarily indicated for managing hypertension and is also used in the treatment of coronary artery disease (CAD). Its sustained duration of action, favorable side-effect profile, and flexibility in dosing make it advantageous as both a monotherapy and as part of combination treatments with other antihypertensive agents. The various formulations and routes of administration, including innovative liquid formulations and novel tablet dosage forms, are aimed at expanding its therapeutic utility and enhancing patient outcomes—especially among populations that may require alternate forms due to swallowing difficulties or pediatric use.

Patent Basics

Definition and Importance of Patents 
Patents represent a crucial element of intellectual property rights, providing innovators with a temporary monopoly granted by the government to exclude competitors from making, using, or selling an invention for a defined period, typically 20 years from filing. In the pharmaceutical arena, patents not only protect the chemical entity but also extend to various aspects such as formulations, methods of manufacturing, and novel therapeutic combinations. This legal protection incentivizes investment into the substantial time and capital required for drug development, ensuring that manufacturers can recoup the costs associated with extensive clinical trials and regulatory approvals.

Patent Process in Pharmaceuticals 
The patent process in pharmaceuticals involves several rigorous steps. It starts with identifying a novel and non-obvious invention, followed by filing a patent application that describes the invention in sufficient detail, including the best mode of carrying out the invention. Patent examiners then review these applications to confirm that all statutory requirements—namely novelty, utility, and non-obviousness—are satisfied. In the fast-evolving field of pharmaceuticals, patents may cover the active pharmaceutical ingredient (API), innovative formulations, methods of use, or specialized manufacturing techniques, each having its own set of challenges and timelines for approval. This multi-layered property protection ensures that different aspects of a drug can potentially be protected by separate patents, thereby extending market exclusivity well beyond the life cycle of the original compound patent.

Amlodipine Patent Landscape

Original Patent Holder 
Historically, the earliest patents covering amlodipine pertained to the base molecule itself. While many know amlodipine commercially under the name Norvasc—a trademark historically associated with Pfizer—the original chemical entity was the subject of patent protection that paved the way for its inclusion in modern cardiovascular therapy. However, the landscape has evolved significantly over time. Early patents for amlodipine were typically held by innovators such as Pfizer, who are credited with bringing the molecule to market. Despite this, the current publicly available patent references mainly reflect subsequent innovations around formulations, combinations, and methods of manufacture rather than the original chemical entity. It is important to note that while the original compound may have been patented by a single entity early on, the current landscape is populated by numerous patents held by various companies focusing on novel delivery systems, combination therapies, or improved stability profiles.

Current Patent Status 
Today, the patent status of amlodipine is characterized by a highly segmented portfolio where various entities hold patents for different formulations, production methods, and combination products containing amlodipine. For example, one patent for a liquid pharmaceutical formulation that is substantially free of water and comprises amlodipine has been granted with current assignees being CMP DEVELOPMENT LLC and LIQMEDS WORLDWIDE LIMITED. Other notable patents—focusing on stable oral formulations of amlodipine for treating hypertension and coronary artery disease—are currently owned by AZURITY PHARMACEUTICALS, INC. Additionally, patents covering unique combinations of amlodipine with other agents, such as losartan, chlorthalidone, candesartan cilexetil, and hydrochlorothiazide, exist and are assigned to different companies including ADAMED PHARMA S.A, MIDAS PHARMA GMBH, and Hanmi-related entities. This diversification within the patent portfolio illustrates how multiple companies continue to innovate on the base compound, thereby extending their market exclusivity through incremental innovation around formulation and therapeutic delivery.

Key Patent Holders Over Time 
Over time, the key patent holders for amlodipine-related technology have shifted and expanded. Initially concentrated on the original discovery of the molecule, later decades have seen a proliferation of patents that focus on improving the drug’s formulation, enhancing its stability, and combining it with other cardiovascular agents. As of the information provided from the Synapse database:

- CMP DEVELOPMENT LLC and LIQMEDS WORLDWIDE LIMITED hold patents for innovative liquid formulations of amlodipine that are substantially free of water, which are designed to improve bioavailability and ease of use. 
- AZURITY PHARMACEUTICALS, INC. has been prominently featured as the current patent holder for stable oral liquid and general liquid formulations of amlodipine designed for the treatment of hypertension and coronary artery disease. 
- Other companies, such as Beijing Sun-Novo Pharmaceutical Research, ADAMED PHARMA S.A, MIDAS PHARMA GMBH, and TAVANTA THERAPEUTICS HUNGARY INCORPORATED, have acquired patents for combination tablets or novel dosage forms that include amlodipine either as a solo agent or in combination with drugs like perindopril, losartan, or chlorthalidone. 
- Patents for specialized formulations such as dry suspensions, freeze-dried orally disintegrating tablets, and even topical gels containing amlodipine have been assigned to companies in diverse geographical regions including China and the United States. 

This mosaic of assignments reflects the decentralized and competitive nature of pharmaceutical innovation, where each company seeks to secure a niche in the market through continuous improvements or novel applications of an established active ingredient.

Implications of Patent Ownership

Market Impact 
The ownership of patents for amlodipine has a profound impact on its market dynamics. Patents secure an exclusive window during which the holders can market their formulation without generic competition, allowing them to recuperate research and development investments through premium pricing. For instance, patents covering refined formulations or combination products not only protect the technological improvements but also create market barriers that can influence pricing strategies and sales volumes. Companies that hold such patents are positioned to negotiate more favorable market terms and can potentially influence healthcare policies regarding drug pricing and substitution. Moreover, the segmentation of patents among various entities fosters competition on the optimization front—different companies may focus on distinct attributes such as bioavailability, stability, or clinical convenience, thus driving gradual improvements in therapeutic outcomes across the entire amlodipine class.

Legal Considerations 
From a legal perspective, the patent portfolio related to amlodipine is continuous evidence of the layered innovation process typical in the pharmaceutical industry. The comprehensive protection offered by multiple patents covering various aspects of a drug’s formulation, method of use, or manufacturing process creates a robust intellectual property shield that can be challenging for competitors to navigate. Firms holding these patents may engage in strategic litigation to enforce their rights, as exemplified by the diverse legal challenges disclosed in related pharmaceutical patent litigation reports. Additionally, the practice of secondary patenting—where companies file new patents for incremental improvements—further extends the period of market exclusivity. This can have significant implications for market competition and may lead to legal disputes about patent validity and inventiveness, particularly when generic manufacturers challenge the enforceability of these secondary patents. The legal landscape is complex and requires continual monitoring by companies to ensure compliance with evolving regulations and to defend their portfolio rights in courts across different jurisdictions.

Future Considerations

Patent Expiry and Generic Competition 
One of the most substantial factors influencing the future of amlodipine technology is the impending expiry or already expired patents on various formulations. As the original patents for the base molecule eventually expire, generic manufacturers are free to enter the market with bioequivalent products, which in turn lead to significant reductions in pricing and an increase in market competition. However, the myriad of secondary patents on innovative formulations, combination therapies, and methods of use can extend market exclusivity well beyond the life of the original compound patent, a phenomenon commonly referred to as “evergreening.” This practice means that even though the core technology might be off-patent, significant portions of the market may still be locked under new protective layers that delay generic penetration. Consequently, it remains essential for regulatory bodies and policymakers to continuously assess these practices, balancing the need for continued innovation with ensuring affordable access to essential medications like amlodipine.

Future Research and Development 
Given the competitive and fragmented nature of the amlodipine patent landscape, future research and development efforts are likely to focus on discovering new delivery systems, expanded combination therapies, and improvements in drug stability and tolerability. Innovative approaches may include developing patient-friendly dosage forms such as orally disintegrating tablets, sustained-release formulations, and even novel liquid formulations aimed at populations with special needs, such as pediatric or geriatric patients. Each of these advances is expected to be supported by its own set of patents, further contributing to the evolving landscape of intellectual property in this area. From a strategic perspective, integrated research efforts that combine pharmaceutical development with targeted patent strategies could potentially offer improved therapeutic outcomes while maintaining commercial viability in the face of generic competition. 

Furthermore, as biomedical research increasingly relies on collaboration between academic institutions and private companies, joint patent applications or licensing arrangements may become more prevalent. These cross-partnership collaborations could prove critical in unlocking new applications for amlodipine, such as its use in novel combination therapies for complex cardiovascular or even metabolic disorders. In addition, advancements in digital patent databases and chemoinformatics tools allow for more streamlined patent searches and analyses, which will further empower stakeholders to navigate the intricate patent environment with greater precision and foresight.

Conclusion 
In summary, the patent for amlodipine is not held by a single entity but rather exists within a multi-faceted, highly competitive environment where different companies hold patents on various aspects of the developmental science behind amlodipine. Early patents on the base molecule were historically associated with innovators such as Pfizer (commercially recognized through Norvasc), but subsequent decades saw a diversification where many companies have secured patents on improved formulations, combination treatments, and novel manufacturing methods. For instance, CMP DEVELOPMENT LLC and LIQMEDS WORLDWIDE LIMITED hold patents for specific liquid formulations, while AZURITY PHARMACEUTICALS, INC. is a prominent holder in the realm of stable oral and liquid formulations. Additional stakeholders, including Beijing Sun-Novo Pharmaceutical Research, ADAMED PHARMA S.A, TAVANTA THERAPEUTICS HUNGARY INCORPORATED, and others, have patented various combination and dosage-specific formulations.

The implications of this diverse patent ownership are significant. They affect market dynamics by offering extended exclusivity, influencing pricing strategies, and shaping the competitive landscape—both legally and commercially. Future considerations will need to factor in patent expiry issues and the balance between innovation and generic competition, which is continuously monitored by regulatory authorities. As newer formulations and advanced delivery systems are developed, the landscape will likely become even more complex, necessitating ongoing strategic and legal assessment.

Curious to see how Eureka LS fits into your workflow? From reducing screening time to simplifying Markush drafting, our AI Agents are ready to deliver immediate value. Explore Eureka LS today and unlock powerful capabilities that help you innovate with confidence.